- Home
- Life Sciences
- Pharmaceutical
- Pharmaceutical Analysis & Statistics in Oceania Countries, December 2012 (p4)
Talk to Robyn
00 1 718 213 49 04
Search inside this page
Publication dates
Publishers
- Global Data (157)
- Business Monitor International (13)
- Global Markets Direct (77)
- GBI Research (5)
- Global Research & Data Services (8)
-
- ICD Research (16)
- Ibisworld (6)
- Euromonitor International (31)
- Datamonitor (23)
- Timely Data Resources Inc. (17)
- Mintel (13)
- VacZine Analytics Group Of Assay Advantage Ltd (9)
- Life Science Analytics (LSA) (8)
- MarketLine (8)
- World Market Intelligence Ltd (8)
- Frost & Sullivan (7)
- Espicom Business Intelligence (6)
- SCRIP Insights (6)
- Obainfo (3)
- ABMRG (3)
- Business Review (3)
- Global Industry Analyst (3)
- Koncept Analytics (3)
- Leatherhead Food Research (3)
- Daedal Research (2)
- Ken Research Private (2)
- Arrowhead (1)
- Bioseeker (1)
- CCM International Limited (1)
- Canadean Ltd (1)
- DrugPatentWatch - ThinkBiotech LLC (1)
- Firstword Pharma (1)
- RNCOS (1)
- Strategic Defence Intelligence (SDI) (1)
- The Economist Intelligence Unit (1)
- Timetric (1)
All regions
data types
Free Market Research Guides to Download
Pharmaceutical Analysis & Statistics in Oceania Countries, December 2012 (p4)
You might be interested in: therapeutics, cancer, drug, more »
» Purchase Premium Reports
91-120 of about 400 reports
Xgeva (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Xgeva (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Xgeva (Prostate Cancer) - Forecast and Market Analysis to 2022?. ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Zometa (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Zometa (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Zometa (Prostate Cancer) - Forecast and Market Analysis to ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Cabozantinib (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Cabozantinib (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Cabozantinib (Prostate Cancer) - Forecast and Market ...
- Industries : Pathology
- Countries : World, Canada, Spain, Italy, France, Germany, Japan, United States, Australia, Europe, United Kingdom
Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Custirsen Sodium (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Custirsen Sodium (Prostate Cancer) - Forecast and ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Sprycel (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Sprycel (Prostate Cancer) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Yervoy (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Yervoy (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Yervoy (Prostate Cancer) - Forecast and Market Analysis to ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Orteronel (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Orteronel (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Orteronel (Prostate Cancer) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Zoladex (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Zoladex (Prostate Cancer) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Alpharadin (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Alpharadin (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Alpharadin (Prostate Cancer) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Lupron Depot (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Lupron Depot (Prostate Cancer) - Forecast and Market ...
- Industries : Pathology
- Countries : Australia, World, Canada, Japan, United States, Spain, Italy, France, Germany, Europe, United Kingdom, Oceania
Tasquinimod (Prostate Cancer) - Forecast and Market Analysis to 2022
- $ 3 495
- Industry report
- December 2012
- by Global Data
Tasquinimod (Prostate Cancer) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Tasquinimod (Prostate Cancer) - Forecast and Market Analysis ...
- Industries : Pathology
- Countries : World, Australia, Canada, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Caldera Health Limited - Product Pipeline Analysis
- $ 750
- Company report
- December 2012
- by Global Data
Summary Caldera Health Limited (Caldera) develops diagnostic devices for the detection of early stage prostate cancer. Its portducts include ProscaNZ, a blood test for prostate cancer, that extends the ...
- Industries : Pathology
- Countries : New Zealand
Biosceptre International Limited - Product Pipeline Analysis
- $ 750
- Company report
- December 2012
- by Global Data
Summary Biosceptre International Limited (Biosceptre) is a biotechnology company. It develops and commercializes antibody materials for the diagnosis and treatment of cancer. The company offers a broad ...
- Industries : Pathology
- Countries : Australia, United States
FBE Pty Ltd - Product Pipeline Analysis
- $ 750
- Company report
- December 2012
- by Global Data
Summary FBE Pty Ltd (FBE) is a biomedical engineering consultancy firm. The company was formed by Flinders Medical Center Foundation (FMCF). FBE provides biomedical engineering consultancy, and medical ...
- Industries : Drug Discovery and Development
- Countries : Australia
Hepatorenal Syndrome - Pipeline Review, H2 2012
- $ 2 000
- Company report
- December 2012
- by Global Markets Direct
Hepatorenal Syndrome - Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Hepatorenal Syndrome - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This ...
- Industries : Pathology
- Countries : World, United States, Australia
Vitamins & Minerals - Australia (2012)
- $ 599
- Industry report
- December 2012
- by Mintel
Vitamins & Minerals in Australia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2012. This market covers single/dual, multi-vitamins and ...
- Industries : Vitamin and Supplement
- Countries : Australia
Orphan Drugs: Market Environment Products and Companies
- $ 1 566
- Industry report
- December 2012
- by Espicom Business Intelligence
The combination of government incentives to develop drugs for rare diseases and the promise of commercial opportunity will continue to fuel the industry's interest in orphan drugs; and provide hope to ...
- Industries : Drug and Medication
- Countries : United States, Australia, Japan, Sweden
New Zealand Pharmaceuticals and Healthcare Industry Update Quarter 1 2012
- $ 1 088
- Industry report
- December 2012
- by Business Monitor International
BMI View: While New Zealand has a highly developed healthcare services system, its pharmaceutical industry is not a particularly attractive prospect for multinationals. Even though the country's risk profile ...
- Industries : Drug and Medication
- Countries : New Zealand
OTC Medications - Australia (2012)
- $ 599
- Industry report
- December 2012
- by Mintel
OTC Medications in Australia by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2012. This market covers analgesics, cough/cold/flu, gastro-intestinal, ...
- Industries : Over-the-counter Drug
- Countries : Australia
PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update
- $ 4 995
- Industry report
- November 2012
- by Global Data
PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, ?PharmaPoint: Rheumatoid Arthritis - Australia ...
- Industries : Pathology
- Countries : Australia
Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Fostamatinib (Rheumatoid Arthritis) Forecast and Market Analysis. ...
- Industries : Pathology
- Countries : Australia, Spain, Italy, France, Germany, Japan, World, United States, Europe, United Kingdom
Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Secukinumab (Rheumatoid Arthritis) Forecast and Market Analysis. ...
- Industries : Pathology
- Countries : Japan, Australia, United States, Spain, Italy, France, Germany, World, Europe, United Kingdom
Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Masitinib (Rheumatoid Arthritis) Forecast and Market Analysis. ...
- Industries : Pathology
- Countries : Australia, Czech Republic, United States, Spain, Italy, France, Germany, Japan, World, Europe, United Kingdom
Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Baricitinib (Rheumatoid Arthritis) Forecast and Market Analysis. ...
- Industries : Pathology
- Countries : Australia, World, United States, Spain, Italy, France, Germany, Japan, Europe, United Kingdom, India
Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Sarilumab (Rheumatoid Arthritis) Forecast and Market Analysis. ...
- Industries : Pathology
- Countries : United States, Spain, Italy, France, Germany, World, Australia, Europe, United Kingdom
Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis. The ...
- Industries : Pathology
- Countries : Australia, World, Spain, Italy, France, Germany, Japan, India, China, United States, Europe, United Kingdom
Humira (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Humira (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Humira (Rheumatoid Arthritis) Forecast and Market Analysis. The ...
- Industries : Pathology
- Countries : Australia, Spain, Italy, France, Germany, Japan, World, United States, Europe, United Kingdom
Remicade (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Remicade (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Remicade (Rheumatoid Arthritis) Forecast and Market Analysis. ...
- Industries : Pathology
- Countries : Australia, World, Spain, Italy, France, Germany, Japan, India, China, United States, Europe, United Kingdom
Simponi (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Simponi (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis. The ...
- Industries : Pathology
- Countries : Australia, Spain, Italy, France, Germany, Japan, World, United States, Europe, United Kingdom
Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis
- $ 3 495
- Industry report
- November 2012
- by Global Data
Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast ...
- Industries : Pathology
- Countries : Australia, Spain, Italy, France, Germany, Japan, World, United States, Europe, United Kingdom
» Download Public Reports
About 1 500 reports
Company Report: Drug Delivery Technology in The United States and Australia for Year 2013
- Company report
- April 2013
- 2 pages
- by Corporation
Novogen Ltd. - Company Report For Year 2013
April 2013The Australian Medicine Industry Brief
April 2013» Read our Company Profiles
12 CompaniesGlaxoSmithKline P.L.C.
United StatesSanofi-Aventis Senegal
SenegalManagement Strategies
United StatesAbbott Laboratories
United StatesJohnson and Johnson
United StatesReportlinker.com © Copyright 2013. All rights reserved.
